At present, no personalized guidelines are available for the prophylactic management of second primary breast cancer in patients with the BRCA1 and BRCA2 pathogenic variants with unilateral breast cancer who underwent BCT as a primary procedure. This evidence concerns the gene BRCA2 and breast carcinoma.